While dopamine D 2 receptor partial agonists (PAs) have been long considered for treating schizophrenia, only one, aripiprazole, is clinically available for therapeutic use. This raises critically important questions as to what is unique about aripiprazole and to what extent animal models can predict therapeutic success. A number of PAs whose clinical fate is known : aripiprazole, preclamol, terguride, OPC-4392 and bifeprunox were compared to haloperidol (a reference antipsychotic) in several convergent preclinical animal models ; i.e. amphetamine-induced locomotion (AIL) and conditioned avoidance response (CAR), predictive of antipsychotic effects ; unilateral nigrostriatal lesioned rats, a model of hypo-dopaminergia ; striatal Fos induction, a molecular marker for antipsychotic activity ; and side-effects common to this class of drugs : catalepsy (motor side-effects) and prolactaemia. The results were compared across drugs with reference to their measured striatal D 2 receptor occupancy. All the PAs occupied striatal D 2 receptors in a dose dependent manner, inhibited AIL and CAR, and lacked motor side-effects or prolactinaemia despite D 2 receptor occupancy exceeding 80 %. At comparative doses, aripiprazole distinguished itself from the other PAs by causing the least rotation in the hypo-dopaminergic model (indicating the least intrinsic activity) and showed the highest Fos expression in the nucleus accumbens (indicating functional D 2 antagonism). Although a number of PAs are active in antipsychotic animal models, not all of them succeed. Given that only aripiprazole is clinically available, it can be inferred that low functional intrinsic activity coupled with sufficient functional antagonism as reflected in the animal models may be a marker of success.
Introduction
Schizophrenia, a complex mental disorder, is a product of genetic vulnerabilities and environmental insults (van Os & Kapur, 2009) . It is thought to arise from a hyperactive subcortical dopaminergic system, causing hallucinations and delusions, and a concomitant underactive cortical dopaminergic system that leads to cognitive and affective disability (Abi-Dargham, 2004 ; Howes & Kapur, 2009) . It has been suggested that partial agonists (PAs) could decrease dopamine transmission post-synaptically in areas that are hyperdopaminergic, as its intrinsic activity is less than that of the natural agonist dopamine, and increase transmission in areas that are hypo-dopaminergic (Lieberman, 2004 ; Stahl, 2001) . However, despite the intuitive appeal of this formulation, until recently, the only medications that had been clinically successful were D 2 receptor (D 2 R) antagonists (Kapur & Mamo, 2003) . A major development of the last few years has been the first successful introduction of a PA antipsychotic : aripiprazole (Kane et al. 2002 ; Potkin et al. 2003) . However, aripiprazole's success comes against a backdrop of a string of failures since the 1970s and hence this study was performed in order to identify the validity of preclinical animal models that have failed to predict clinical failure (Bolonna & Kerwin, 2005 ; Tamminga, 2002) .
Several PAs have been evaluated and compounds like preclamol, terguride, roxindole, talipexole, (+)-UH232, OPC-4392 and bifeprunox have reached various stages of clinical development to treat schizophrenia without becoming clinically available (Agid et al. 2008 ; Tamminga, 2002) . This raises several critically important questions. What is unique about aripiprazole? Why did aripiprazole succeed where others failed? Has it met its predicted success in stabilizing dopaminergic transmission? Can we rely on preclinical tests to screen for successful PA antipsychotics? To address these questions, we chose PAs that had been tested in humans but failed to receive clinical approval and compared them to aripiprazole and haloperidol in preclinical animal models : (i) preclamol [(S)-(3-hydoxyphenyl)-N-n-propylpiperidine], also known as (x)3-PPP (Wikstrom et al. 1984) ; (ii) terguride (transdihydrolisuride), a derivative of lisuride and chemically similar to the ergoloid LSD (Koller & Herbster, 1987) ; (iii) OPC-4392, a quinolinone derivative and precursor in the series that led to the discovery of aripiprazole (Banno et al. 1988 ; Kiuchi et al. 1988) and ; (iv) bifeprunox (DU-127,090), a 1-aryl-4-(biarylmethylene) piperazine derivative (Feenstra et al. 2001) . Preclamol and terguride have been reported to be clinically efficacious for very short periods (Lahti et al. 1998 ; Olbrich & Schanz, 1991) , OPC-4392 has been reported to aggravate positive symptoms in patients (Kikuchi et al. 1995) and bifeprunox has received mixed clinical reports of efficacy and has not been approved for long-term therapy by the US FDA (Casey et al. 2008 ; Newman-Tancredi et al. 2007) . While these molecules have affinity to other receptors, the main reason for their consideration in schizophrenia was their PA activity at dopamine D 2 Rs.
To compare and contrast the PAs, in vitro, for their actions on dopamine D 2 Rs, the published results by Tadori et al. (2005 Tadori et al. ( , 2009 ) have been collated in Table 1 . The selection from a single laboratory was made as none of the other studies have compared the PAs chosen in this study in similar test systems. They have very high affinity with the exception of preclamol ; in the in-vitro model, aripiprazole has the least agonist potency (as assessed by inhibition of forskolin-stimulated cAMP accumulation) and in terms of antagonist activity, terguride and bifeprunox are more potent than aripiprazole (as assessed by potency to reverse dopamine inhibition of forskolinstimulated cAMP accumulation). A limitation of any in-vitro comparison is that it cannot accurately model brain occupancy of the drug, the level of endogenous transmission or the precise level of ' spare receptors ' in the relevant functional system that characterize the net functional effects of PAs (Strange, 2008) . Hence, it is important to understand the role played by all these factors at the systems level, in-vivo. We started by first examining in-vivo D 2 R occupancy (D 2 RO) and all the PAs exhibited dose-related D 2 RO. It became clear in occupancy studies that in the case of bifeprunox, D 2 occupancy was slower in onset and hence the timings of all related assays were adjusted to accommodate this. We then examined the PAs in widely accepted behavioural models as a function of D 2 RO : amphetamine-induced locomotor activity (AIL), conditioned avoidance response (CAR) and catalepsy. Further, the ability of PAs to induce rotation in a hypodopaminergic model [unilateral 6-hydroxydopamine (6-OHDA) nigrostriatal lesioned animals] was measured. Preferential action on the limbic (nucleus accumbens vs. dorsolateral striatum) system was examined by measuring Fos protein induction. Last, the effect on the tuberoinfundibular system was evaluated by measuring plasma prolactin levels.
Methods and materials

Animals
Adult male Sprague-Dawley rats (Charles River Laboratories, Canada), weighing 250-275 g on arrival, were housed in pairs on a 12-h reversed light/dark cycle (lights on 19 : 00 hours) and maintained at 21¡1 xC with a relative humidity of 55-60 %. They had access to food and water ad libitum and were allowed to habituate for at least 1 wk before experimentation. All animal experiments were approved by the Animal Care Committee of the Centre for Addiction and Mental Health, Toronto.
Drugs
Preclamol hydrochloride, terguride and haloperidol (Sigma-Aldrich) were dissolved in acidified saline (glacial acetic acid, 1 % v/v). OPC-4392, bifeprunox mesylate and aripiprazole (Toronto Research Chemicals, Canada) were dissolved in 30 % v/v dimethylformamide in saline acidified with glacial acetic acid (1 % v/v). All drugs were administered subcutaneously (s.c.) in a volume of 1 ml/kg body weight in rats. (Wadenberg et al. 2000) . An animal was considered cataleptic with a score of o2 and the ED 50 values were determined using probit analysis software (SPSS Inc., USA).
AIL
The effect of drugs on AIL were evaluated in computerized locomotor activity boxes (27r48r20 cm boxes with photobeams). Bifeprunox was injected 4 h prior to d-amphetamine injection while for all other drugs it 
CAR
Rats were habituated to two-way shuttle boxes (Med Associates, USA) and were trained for 5 d (each day consisted of 40 trials) to avoid a scrambled 0.8 mA shock (unconditioned stimulus) that appeared 10 s later following presentation of an 80-dB white-noise (conditioned stimulus) (Wadenberg et al. 2001) . A micro-switch system identified the location of the rat in the two-compartment shuttle box and a computer program controlled the operations. Rats that moved to the other side of the box within the period of the conditioned stimulus (10 s) were noted as having made an 'avoidance ' response. Those who escaped the shock in the next 20 s were termed as having 'escaped ', and those that did not escape were termed as ' escape failures '. Animals that completed the last training session with a reliability of at least 80 % were chosen for testing and rats of each drug group served as their own controls in a within-subject design, balanced as far as possible. Animals were tested prior to drug administration, 20, 90, 240 min, 24 h and if needed 48 h after drug administration with an interval of at least 2 d between experiments. In the case of bifeprunox, CAR was evaluated up to 1 wk after drug administration as the highest dose chosen for the study had a long duration of action and an interval of 1 wk was selected for repeated-measures evaluation. Each session consisted of 20 trials and a minimum of six animals were used for each drug. The ED 50 for CAR was the dose required to produce 50 % inhibition of avoidance, and was calculated using nonlinear regression [hyperbola : f=x/(a+b*x) using Sigma Plot software] at appropriate time-points were maximal efficacy was displayed (240 min for bifeprunox, 90 min for the other drugs).
Contralateral rotation (CR) in unilateral 6-OHDA nigrostriatal lesioned animals
Rats received a unilateral 6-OHDA lesion of the nigrostriatal dopamine pathway. They were pretreated with desipramine hydrochloride (Sigma-Aldrich ; 15 mg/kg i.p.) (Breese & Traylor, 1971 ) and were anaesthetized with sodium pentobarbital (52 mg/kg i.p. ; Euthanyl 1 , MTC Pharmaceuticals, Canada).
Approximately 30 min after administration of desipramine, a 26-gauge stainless-steel injector was lowered into the medial forebrain bundle (coordinates : ML ¡0.15 cm, AP x0.34 cm, DV x0.85 cm) and 4 mg 6-OHDA (Sigma-Aldrich ; dissolved in 8 ml of a 0.9 % NaCl/ascorbic acid solution) was infused over an 8-min period, at a flow rate of 0.5 ml/min. The injector was left in place an additional 2 min to minimize diffusion upward into the injector tract. Animals received a lesion either in the left or right hemisphere randomly. After a 2-wk recovery period, the development of denervation supersensitivity was assessed by administering apomorphine (0.05 mg/kg s.c. ; SigmaAldrich) and measuring CR. At this dose, apomorphine produces marked circling behaviour only if animals are depleted of >90 % of the dopaminergic input to the striatum (Marshall & Ungerstedt, 1977) . CR was measured using Roto-Rat apparatus (Med Associates Inc., USA) which consisted of a test bowl 45.7 cm in diameter at the top and 15.2 cm deep, in which the animals were tethered using a body jacket to an optical encoder that measured rotations (360x) and readings were recorded on a computer for analysis. The animals were habituated to the body jacket 1 d prior to the first recording and were allowed to habituate to the test apparatus for 15 min prior to every drug administration. Rats were observed 10 min after the apomorphine injection, and animals that met a criterion >5 full rotations in a 1-min period were chosen. CR was measured for a period of 30 min, immediately after injection, with the exception of bifeprunox, when it was measured for a similar period, 2 h after administration. Rats of each drug group (n=5) served as their own control in a within-subject design and their CR was compared to a dose of apomorphine (dose 0.1 mg/kg). The drug doses and apomorphine were administered in a random sequence and testing was conducted with an interval of 2 d between experiments or in the case of bifeprunox, 1 wk apart.
Fos immunohistochemistry in rats
Rats were anaesthetized using sodium pentobarbitone (100 mg/kg i.p.) and brains removed after transcardial perfusion with saline followed by paraformaldehyde (4 %). The brains were transferred to sucrose solutions (10 % for 2 h, 20 % for 12 h, 30 % for 24 h), dried, and stored at x80 xC until processing. In the case of bifeprunox, rats were anaesthetized and perfused 6 h after drug administration while in the case of all other drugs it was 2 h after drug administration. Fosimmunoreactive nuclei, labelled with antiserum raised in rabbits against the Fos peptide 4-17 amino acids of human Fos (Oncogene Research Products, USA), were counted within a 400r400 mm grid at a magnification of 100rin the shell of the nucleus accumbens and dorsolateral striatum (bregma 1.70-1.00) (Paxinos & Watson, 1986 ; Robertson et al. 1994) . A minimum of four animals were used for each test dose.
Plasma prolactin measurements
Prolactin levels (ng/ml) were measured using plasma collected from rats sacrificed for the D 2 RO experiments using a rat prolactin enzyme immunoassay kit (ALPCO Diagnostics 1 , USA).
Results
Receptor occupancy and catalepsy
All the drugs showed a dose-dependent D 2 RO (Fig. 1 , 
Inhibition of AIL activity
All the drugs effectively antagonized AIL (Fig. 2 , Table 2 ). The ED 50 values for the various antipsychotics 1 h after administration were : haloperidol, 
Inhibition of CAR
Inhibition of CAR was demonstrated in a dose-related manner by all the drugs (Fig. 3, Fig. 2 . Effect of subcutaneous administration of haloperidol, preclamol, terguride, OPC-4392, bifeprunox and aripiprazole on locomotor activity measured for 1 h duration after subcutaneous amphetamine administration. The drugs were administered 1 h prior to amphetamine administration with the exception of bifeprunox where it was administered 4 h prior to stimulant administration. The values are expressed as mean¡S.E.M and five animals were used at each dose-point. The vehicle group illustrated is the cumulative mean of all vehicle-treated animals after a saline injection (the vehicle for amphetamine). ** p<0.01, * p<0.5, one-way ANOVA : F 25,154 =25.6 ; Dunnett's post-hoc test (two-sided) with respect to amphetamine treatment using SPSS software. 240 min after administration and it resulted in an ED 50 value of 1.28 mg/kg (95 % CI 0.28-2.28). It took nearly a week for bifeprunox's highest dose group (10 mg/ kg) to return to baseline in contrast to all other drugtreated animals, which returned to baseline 24 h after drug administration (an allowance was made for this in repeated testing). Escape failures were <5 % for any drug doses tested at any of the time-points.
CR
All the D 2 PAs with the exception of aripiprazole were able to evoke significant CR (Fig. 4) . We compared the different PAs with respect to their ability to induce 50 % CR compared to a single dose of apomorphine (0.1 mg/kg) as a factor of their D 2 RO (Tables 2, 3 ). The D 2 RO values corresponding to their ED 50 values were : preclamol, 37 % ; terguride, 62 % ; OPC-4392, 39 % ; bifeprunox, 91 % ; and in the case of aripiprazole it was not determined as the highest dose tested (>90 % D 2 RO) had not achieved 50 % CR.
Fos induction
Fos protein induction in the nucleus accumbens (shell) as well as the dorsolateral striatum was measured over different doses along the D 2 RO curve (Fig. 5, Table 4 ). Haloperidol clearly showed a dose-related increase of Fos induction in the shell of the nucleus accumbens which correlated with its antipsychotic activity. A certain threshold (>30 Fos counts) emerged with respect to aripiprazole differentiating itself from other PAs. As observed in the dorsolateral striatum, none of the PAs with the exception of aripiprazole, expressed statistically significant Fos protein. When compared to haloperidol, the expression of Fos (>30 Fos counts) in the dorsolateral striatum correlated with catalepsy which none of the PAs achieved. Among the PAs a dichotomy emerged ; aripiprazole was able to express high levels of Fos in the nucleus accumbens shell compared to the other PAs and in the case of terguride and bifeprunox, Fos expression was distinctively absent at comparable D 2 RO.
Prolactin levels
Haloperidol showed significant dose-related prolactin elevation while none of the PAs with the exception of aripiprazole at a single dose-point caused prolactin elevation (Table 5 ). There was a trend towards lowering of plasma prolactin values in the case of preclamol and terguride but it was not statistically significant. However, when the haloperidol group was removed from the dataset, terguride caused a statistically significant decrease in prolactin levels [one-way ANOVA : F 25,124 =10.34, Dunnett's post-hoc test (two-sided) with respect to vehicle treatment] for all the doses tested. Fig. 3 . The effects of subcutaneous administration of haloperidol (n=8), preclamol (n=7), terguride (n=8), OPC-4392 (n=8), bifeprunox (n=7) and aripiprazole (n=7) on conditioned avoidance response expressed as a percentage of 20 trials measured 90 min after drug administration with the exception of bifeprunox where it was measured 4 h after drug administration. The animals served as their own controls in a within-subject design and values are expressed as mean¡S.E.M. The percentage avoidance values were analysed in a repeated-measures ANOVA with dose (vehicle, three doses) as a within-subjects factor for each drug separately and the main effect of dose was significant at least at one time-point for all the drugs. Post-hoc comparisons were performed using Bonferroni adjustment for multiple comparisons and the level of significance indicated in the figure is that with respect to vehicle treatment (** p<0.01, * p<0.05) ; all analysis were performed using SPSS software.
Discussion
The search for PAs for schizophrenia has been a quest for over three decades which still continues (Brennan et al. 2010 ; Kiss et al. 2010 ; Rotella et al. 2009 ; Yan et al. 2010) . Several such compounds have been identified in the laboratory and the challenge is to predict clinical success. As of our writing, only one compound, aripiprazole, has been an unequivocal success. Unlike D 2 antagonists where a measure of affinity is enough to predict functional effects, the situation in PAs is decidedly more complex. The net effect of PAs is dependent not only on its affinity for D 2 and the dose, but on its tissue-specific, and even second-messengerspecific intrinsic activity (Strange, 2007 ; Urban et al. 2007) . While the measurement of intrinsic activity in a test tube can be standardized, functional intrinsic activity in a living system is determined by receptor occupancy levels, spare receptors, and the level of endogenous neurotransmitters, the precise levels of which are unknown and unable to be satisfactorily modelled in vitro (Strange, 2008) . Because of these complexities, perhaps, no simple in-vitro measure predicts why aripiprazole succeeds and others fail. In the present study, we have employed the conventionally used preclinical animal models, supplemented by measures of in-vivo occupancy, to determine the preclinical indices that best associate with clinical success. A number of drugs fail clinically due to nonpharmacological reasons which include bioavailability, metabolic stability, side-effects and ineffective engagement of target. The PAs selected for this study were reported to have lacked clinical success primarily due to insufficient efficacy. The drugs preclamol, terguride and OPC-4392 were not evaluated using D 2 -PET imaging techniques in humans and there is no confirmation that the target (D 2 Rs) was sufficiently engaged. However, these drugs were tested at very high doses that should have engaged the target (based on their affinity for the target) in clinical trials and from animal studies it is clear that they are able to cross the blood-brain barrier readily.
The findings across the PAs lead to some converging themes. First, all the PAs (the effective as well as the failed ones) are active in the AIL test ; thus, the standard AIL has high sensitivity, but no ability to differentiate between effective and ineffective antipsychotics. Second, all the PAs (the effective as well as the failed ones) are active in the CAR test ; thus, the standard CAR also has high sensitivity, but no ability to differentiate between effective and ineffective antipsychotics. Thus, the two tests routinely used to triage Fig. 4 . The ability to cause contralateral rotation (CR) by preclamol, terguride, OPC-4392, bifeprunox and aripiprazole in unilateral nigrostriatal 6-OHDA lesioned rats is illustrated in the figure as a percentage of 0.1 mg/kg s.c. apomorphine response. The animals served as their own controls in a within-subject design (n=5 for each drug) and values are expressed as mean¡S.E.M. CR was measured for 30 min after subcutaneous administration of the partial agonists and in the case of bifeprunox, CR was measured for 30 min, 2 h after drug administration. The percentage CR values were analysed in a repeatedmeasures ANOVA with dose (vehicle, three doses) as a within-subjects factor for each drug separately and the main effect of dose was significant at least at one time-point for all the drugs, except aripiprazole. Post-hoc comparisons were performed using Bonferroni adjustment for multiple comparisons and the level of significance indicated in the figure is that with respect to vehicle treatment (* p<0.05) ; all statistical analysis were performed using SPSS software.
antipsychotics give a positive signal for all the tested PAs (this is perhaps why they were clinically approved), but we know in retrospect that these tests do not have the required specificity in this context. Third, unlike the traditional antagonist antipsychotics, PAs need a much higher D 2 RO to achieve equivalent efficacy in the CAR model (>80 % D 2 RO) (Natesan et al. 2006 (Natesan et al. , 2008 . This finding is clearly reflected in the clinical situation where aripiprazole is effective in a dose range (10-30 mg/d) where it leads to >80 % D 2 RO compared to 60-80 % D 2 RO range for the traditional antagonist antipsychotics (Mamo et al. 2007) . However, what is also clear is that just high levels of achievable D 2 RO by a PA do not provide antipsychotic efficacy in animal models or in the clinical setting.
The test where both the effective antipsychotics (haloperidol and aripiprazole) are similar, and are different from the other failed PAs, is Fos induction in the nucleus accumbens. Fos is a protein belonging to the immediate early genes family and is normally the first sign of a genomic response to a variety of stimulus (Sheng & Greenberg, 1990) . Antipsychotics alter Fos expression in a number of brain regions including the nucleus accumbens and dorsolateral striatum. Fos increases in the two regions have been identified as Values are mean¡S.E.M. and all drugs were administered subcutaneously. CR per se was not statistically analysed as intra-subject variation was very high to agonist responses. Percentage CR with respect to apomorphine was analysed using repeated-measures ANOVA with dose (vehicle, three doses) as a within-subject factor for each drug separately and was carried out post-hoc using Bonferroni adjustment for multiple comparisons, if needed ; the level of significance indicated in the table is that with respect to the vehicle treatment (* p<0.05). a Average of individual animal's response with respect to their within-subject apomorphine response.
markers for antipsychotic efficacy and motor sideeffects profile, respectively (Robertson et al. 1994 ; Sumner et al. 2004) . The induction of Fos in the striatum by antipsychotics involves D 2 Rs, is a measure of in-vivo functional antagonism in the accumbens, and can be reversed by D 2 agonists (Dragunow et al. 1990 ; Miller, 1990) . Hence, this marker serves as an indicator of overall functional antagonism, a molecular index that reflects the balance of antagonism and intrinsic activity afforded by the drugs, within a functional system, at the given doses. While both aripiprazole and haloperidol induce Fos to substantial levels, they do so at very different levels of occupancy : haloperidol's non-cataleptic efficacious dose range of 0.05-0.1 mg/kg represents a D 2 RO of 67-78 % while aripiprazole's efficacious dose range of 10-60 mg/kg represents a D 2 RO of 81-87 %. Thus, the data suggest that for a PA to be functionally effective, the combination of its occupancy and intrinsic activity are integral to its success. While the failed PAs achieve high levels of D 2 RO, not all of them induce nucleus accumbens Fos, indicating less functional antagonism. A close look at Table 4 reveals that Fos is induced significantly by preclamol and OPC-4392 at the highest doses but, it does not exceed the 30 plus threshold as seen in the case of aripiprazole and haloperidol. This is also reflected in the hypodopaminergic model where aripiprazole at doses >80 % D 2 RO causes the least rotation among the PAs and we believe this is reflected in the extent of Fos expression at similar dose levels.
In the side-effect profile all the PAs score well. The PAs have very low liability for motor side-effects in spite of very high occupancy and are devoid of prolactinaemia (Potkin et al. 2003) . Thus it seems that to get an effective PA antipsychotic with minimal sideeffects, the key issues are to find drugs that provide high enough D 2 RO at clinically relevant doses with sufficiently modest intrinsic activity such that the net effect is one of traditional antipsychotic-like functional antagonism, as shown by robust Fos induction in the nucleus accumbens. There has been an elevated incidence of nausea reported with PAs having higher intrinsic activity and such incidence has been reported with preclamol, terguride, OPC4392 as well as bifeprunox in comparison to aripiprazole (Barbato et al. 2006 ; Krause et al. 1990 ; Murasaki et al. 1988 ; Potkin et al. 2003 ; Tamminga et al. 1992) . As rodent models are not suitable to measure emesis, animal models of ferrets or dogs could possibly be used to differentiate PAs for their liability to cause nausea or emesis and possibly aid in screening candidate molecules. There are a number of limitations to the study and hence caveats to our conclusions. The PAs have affinity to a number of other receptors, including dopamine D 3 (Tadori et al. 2008 ), which we have not studied explicitly in this study. Moreover, D 3 R selective antagonists developed so far have failed to demonstrate sufficient antipsychotic effects in animal models (Millan et al. 2000 ; Reavill et al. 2000) . The other significant interactions they have are as follows : preclamol : sigma s 1 (Largent et al. 1984) ; terguride : serotonin 5-HT 1A,2A , alpha a 1A,2A,2B,2C (Millan et al. 2002) ; OPC4392 : serotonin 5-HT 7 (Lawler et al. 1999) ; bifeprunox : serotonin 5-HT 1A (Newman-Tancredi et al. 2005) ; aripiprazole : serotonin 5-HT 1A,2A,7 , 1A , histamine H 1 (Shapiro et al. 2003) . Thus, we cannot rule out that some of the actions could be influenced by activity at other receptors, the common denominator is their actions at the dopamine D 2 R. Aripiprazole is known to have active metabolites in rats and humans. While the rodent metabolite (DM-1451) is an antagonist, it is known to cross the blood-brain barrier poorly (Wood et al. 2006) . Dehydroaripiprazole, the active human metabolite is a partial D 2 agonist and accounts for 25-40 % of the active moiety in blood plasma levels (Kim et al. 2008 ; Mamo et al. 2007) . It has similar affinity to D 2 Rs as aripiprazole and has similar intrinsic activity (Wood et al. 2006 ) which makes its likely that the pharmacological contribution will be similar to the parent compound. In any case, this is a limitation of the present study where species differences in active metabolites could limit translation of findings. While we have focused on receptor binding and occupancy, it is now recognized that PAs can be biased in recruiting different second-messenger systems related to D 2 R signalling (Urban et al. 2007 ). The dopamine D 2 R signals by two independent pathways, the classical G-protein coupling (cAMP turnover) and the b-arrestin-mediated pathway (Beaulieu et al. 2005) . Previously, b-arrestins were thought to be involved only in desensitization and trafficking, but they also play an important role in signalling, and there is evidence that there could be bias in choosing either of these pathways by agonists thus leading to differences in their therapeutic or side-effect profile (Rajagopal et al. 2010) . The literature on aripiprazole is mixed, while Masri et al. (2008) claim aripiprazole to be a PA at the G-protein arm and an antagonist at recruiting b-arrestin, Klewe et al. (2008) claim they have similar efficacy as a PA on both these arms. In any case, these Values are expressed as mean¡S.E.M., ng/ml. Plasma was collected from animals sacrificed in order to determine striatal occupancy (n=5 for each dose-point, 1 h post treatment except for bifeprunox which was determined at 4 h) after subcutaneous administration of the drug. One sample in the haloperidol group of 1 mg/kg was contaminated and was not used for the analysis. The vehicle group is the cumulative value of the different vehicles used for the study, the means of which did not significantly differ from each other. * p<0.01, one-way ANOVA : F 29,144 =16.81 ; Dunnett's post-hoc test (two-sided) with respect to the cumulative vehicle control using SPSS software.
actions must have been reflected in the in-vivo models that we have studied and further experimentation is needed to determine if differential actions on these pathways influence clinical outcome. The animal model of hypo-dopaminergia used in the study is an extreme one (necessary to differentiate weak PAs) and may not resemble human conditions of modest prefrontal hypo-frontality. As aripiprazole is able to elicit a very weak response in this extreme model it is not clear if the low degree of intrinsic activity that is necessary for success in treating psychosis will simultaneously be effective against hypo-frontality. Thus, this remains an open question. Finally, the functional models used here are singledose acute models, while it is clear that antipsychotics do not reach full effectiveness after a single dose. Thus, these models are, at best, predictively useful, rather than mechanistically precise. Future systematic studies could examine how the effects of these drugs evolve on sustained treatment.
In summary, after three decades and several failures interest still continues in designing new PAs. If aripiprazole is to be considered a template for success then the main message is that the simple traditional 'hyper-dopaminergic ' models are insufficient. While they certainly have the sensitivity, they do not have sufficient predictive value. The two messages that emerge are that aripiprazole's success may be related to its modest intrinsic activity, and that the Fos induction model, insofar as it provides a functional assay that combines occupancy and intrinsic activity in a living system provides the best predictive value in this context. The challenge, of course, is that the lessons discerned here are in the context of dopamine-dependent antipsychotics. Whether any of these models would have predictive value in examining totally novel mechanisms (e.g. mGluR agonists ; Patil et al. 2007) , is unclear. However, that question cannot be rationally answered until there is the first successful clinical antipsychotic that does not utilize the dopaminergic system. Until we get there, we believe the findings reported here provide some guidance to those considering the development of novel PAs. However, it is not clear if aripiprazole has the optimum efficacy of a PA and the predictive criteria have been established retrospectively.
